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Vaccination  programs  employing  capsular-based  meningococcal  vaccines  have  proved  successful  in a
variety of  settings  globally  since  ﬁrst  introduced  over  40 years  ago.  Similar  successes  have  been  demon-
strated  using  meningococcal  vaccines  for use  against  serogroup  B  (MenB)  outbreak  strains  but the
diversity  of MenB  strains  has  limited  vaccine  use  outside  targeted  geographic  regions.  MenB  contin-
ues  to be  a signiﬁcant  cause  of  outbreaks  in adolescents  and  young  adults,  as recently  demonstrated  in
university  settings  in  the  US  (Princeton,  New  Jersey  and Santa  Barbara,  California)  and has  the potential
for hyperendemic  disease  levels  such  as  currently  experienced  in  Québec  and  the  United  Kingdom.  In
adolescents,  increased  endemic  disease  rates and  outbreak  potential  are  likely  associated  with  social
behaviors  putting  individuals  at risk  for carriage  acquisition  and  may  explain  regional  and  temporal  vari-
ations  in  epidemiology.  A  protein-based,  multi-component  MenB  vaccine  (4CMenB)  is  currently  licensed
for use  in 37  countries  including  EU/EEA  countries,  Australia,  Canada,  Chile,  Colombia,  Uruguay,  and  the
US.  In this  article  we  review  the most  recent  clinical  trial data  with  4CMenB  with  a focus  on  adolescents
and  young  adults.  The  vaccine  appears  to  have an  acceptable  safety  proﬁle  and  is  well-tolerated  in  ado-
lescents  and  young  adults  while  providing  robust,  persistent  levels  of bactericidal  antibodies  considered
protective  for each  of  the  four  antigenic  components  of  the vaccine.  With  the  recent availability  of  this
vaccine,  health  care  providers  have  the  ﬁrst  comprehensive  opportunity  to control  meningococcal  dis-
ease,  a highly  disruptive  public  health  problem  with  a disproportionate  impact  on adolescents  and  young
adults.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. IntroductionThe bacterium Neisseria meningitidis, also known as meningo-
occus, can cause infections of the meninges as well as sepsis. N.
eningitidis infection can lead to invasive meningococcal disease
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(IMD) which is responsible for serious morbidity and mortality with
global estimates of 50,000–135,000 deaths annually [1,2]. Seque-
lae can include limb loss, cognitive impairment, developmental
delays, and focal neurological deﬁcits [3]. Both disease burden and
serogroup distribution vary across geographic regions and over
time. The vast majority of IMD  cases are caused by serogroups A, B,
C, W,  and Y.
Meningococcal disease due to serogroup B (MenB) remains
endemic in many countries in Europe, Western Paciﬁc, and the
Americas where incidence rates are dynamic over time. The major-
ity of IMD  cases across Europe from 2008–2009 were caused by
serogroup B (71%), and the incidence rate for adolescents aged
15–19 years in 2009 was approximately 1.7 cases per 100,000
population [4]. Australia and New Zealand report similar inci-
dence rates [5–8]. Low to moderate endemic rates (of predominant
serogroup B) in the Americas range from 0.3 to 4 cases per 100,000
population [1,5,9].
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Adolescents and young adults are unique in both their suscepti-
ility to IMD  and as vaccine targets to impact carriage rates, thereby
eading to ‘herd protection’. While the incidence of meningococcal
isease is highest in infants <1 year of age, there tends to be a second
eak in adolescents, aged 11–19 years [1]. Nasopharyngeal carriage
s more prevalent among adolescents [10]. The high carriage rate
nd peak of disease incidence in adolescents and young adults is
hought to be due largely to factors associated with social behav-
ors. Various studies have shown that increased meningococcal
isease incidence, carriage, and transmission among adolescents
s linked to activities such as close living quarters (e.g. univer-
ity dormitories, military barracks), crowded venues (e.g. bars,
lubs), intimate contact (e.g. kissing, sharing drinks), smoking, and
leep deprivation [11–13]. While incidence peaks in adolescents
re common in countries like the US, Canada, and Europe, some
ountries in Latin America do not exhibit such a prominent peak
n its adolescent population [14–17]. This observation may  be in
art due to differences in college/university systems where, for
xample, dormitory housing is more common in the US but not
n Chile.
When new meningococcal clones circulate in a naïve popula-
ion, there tends to be a typical epidemiologic age distribution. In
uébec, Canada, as previously reported in Oregon, US, an increase
n disease incidence associated with a MenB clonal complex was
rst seen in 15–24 year-olds prior to its general distribution across
he population [18,19]. This observation, in addition to the high
arriage rate and increase in disease incidence among adolescents,
ighlights the potential impact of vaccinating adolescents and
oung adults, not only to protect vaccinated individuals from IMD
ut also to build ‘herd protection’. Vaccinating adolescents prior to
arriage acquisition could potentially impact carriage in this high
isk age group that currently acts as a reservoir of meningococcal
isease. This is an important public health goal because population
mmunity makes it less likely for future outbreaks to occur in any
ge group [10].
Decades of investigations into the etiology, pathogenesis, and
nterventions to treat or prevent IMD  have reduced its impact glob-
lly, but serogroup B meningococcal disease remains feared and
ts prevention an unmet medical need. Apart from infants who
re at highest risk, adolescents and young adults are at particular
isk, with demonstrated increased risk for outbreaks and hyperen-
emic disease. The recent licensure of 4CMenB (Bexsero®, Novartis
accines), a multicomponent, protein-based MenB vaccine, pro-
ides a promising opportunity to impact MenB disease. Here, we
eview meningococcal vaccination strategies in adolescents and the
vailable data from adolescents and young adults after vaccination
ith 4CMenB, and discuss the potential beneﬁts of this vaccine
n protecting against IMD, particularly in these vulnerable age
roups.
. Worldwide meningococcal vaccination strategies in
dolescents
There are several examples in which comprehensive meningo-
occal disease control has been accomplished on a national level,
sing either capsular-based or protein-based meningococcal vac-
ines. The UK introduced a meningococcal conjugate vaccine
gainst serogroup C (MCCV) in 1999, initially for individuals up to
8 years of age, and infections due to serogroup C were reduced
y 86.7% thereafter [20,21]. The health ministry in the Netherlands
ffered a MenC conjugate vaccine in 2002 to toddlers at 14 months
f age followed by a national catch-up campaign for those aged
–18 years [22]. Canada and the US currently recommend a quadri-
alent conjugate vaccine (MenACWY) for routine use in adolescents
ged 11–18 years. Although a cause and effect relationship can-
ot be deﬁnitively established in each of these examples, current (2015) 4437–4445
disease incidence of meningococcal serogroups targeted by these
vaccines remains at historically low levels.
Countries like New Zealand and Cuba have implemented
national or regional immunization campaigns to control MenB
disease epidemics that included children, adolescents, and/or
young adults utilizing outer membrane vesicle (OMV)-based vac-
cines. Cuba mandated a nationwide intervention in 1989 to
immunize individuals less than 20 years of age against meningo-
coccal serogroups B and C using the VA-MENGOC-BC vaccine
[23]. This vaccine strain (Cu385/83; B:4:P1.15) consisted of
lipooligosaccharide-depleted outer membrane proteins and group
C polysaccharide enriched with enveloped proteins [23]. After vac-
cine introduction, from 1984–1994 the incidence fell from 14.1 to
0.8 cases per 100,000 person-years [24]. In another instance, New
Zealand implemented an infant and adolescent vaccination strat-
egy from 2004 to 2008 to curb a 13-year epidemic against a clonal
outbreak of MenB [25]. The vaccine used was a meningococcal OMV
vaccine (MeNZB®), which was offered to high risk groups aged
6 months to 19 years. Studies have shown a substantial vaccine-
attributable decline of the epidemic [26].
2.1. Strengths and limitations of immunizing adolescents and
young adults
These national campaigns that aimed to reduce MenB or MenC
disease incidence by including all age groups at increased risk for
meningococcal disease in order to both control IMD  and to prevent
future outbreaks appear to have been successful. For example, in
the MenC campaign in the UK that began in 1999, MCCV was offered
to adolescents aged 15–17 years (the highest risk group), followed
by catch-up vaccination for 12–15 year-olds while also offered to
infants in order to cover the high-risk groups. In 2000, a conjugate
or polysaccharide MenC vaccine was then offered to ﬁrst-year uni-
versity students and was subsequently made available to children
and young adults ≤25 years of age [21]. As expected, a decrease
in IMD  cases was ﬁrst observed in the age groups that were ﬁrst
immunized, followed by reductions in other age groups. The num-
ber of cases continued to decrease and in 2007/2008 had dropped
to levels 97% below those reported in 1998/1999 [21].
Vaccine compliance tends to be sub-optimal in adolescents,
particularly for multi-dose vaccine series [27–29]. Reasons for sub-
optimal compliance in adolescents include but are not limited
to: infrequent healthcare visits, lack of health insurance, poor
provider communication on the need to complete vaccine series,
and patient/parent failure to return for completion of dose-series
[29]. Vaccination against human-papillomavirus (HPV) is a case in
point. The National Immunization Survey-Teen has collected vacci-
nation information on adolescents aged 13–17 years in the US since
2006. This study showed that although HPV coverage increased
since 2006, in 2012, 54% (52–56%) of adolescent girls had received
a single dose, 43% (32–35%) had received 2 doses and only 33%
(32–36%) had completed the 3-dose series [27].
3. Use of a multicomponent MenB vaccine in adolescents
and young adults
Use of a meningococcal vaccine derived from OMVs has been
associated with clinical effectiveness in controlling regional out-
breaks of speciﬁc strains of MenB as outlined above. Experience
in past MenB outbreaks showed that PorA is the immunodomi-
nant antigen in OMV  [30–32]. However, due to the speciﬁcity of
the immune response to PorA and the diversity of PorA antigens
present in meningococcal serogroup B strains, these tailor-made
vaccines, which were effective against the strains that they were
designed to combat, were poorly immunogenic against heterolo-
gous strains. In order to provide broad protection against MenB,
T. Nolan et al. / Vaccine 33 (2015) 4437–4445 4439
Table  1
Summary of 4CMenB studies in adolescents and adults.
Study (year) Study objectives Location Participants vaccinated Reference
Kimura et al. (2011) Safety, tolerability, and immunogenicity of 3
doses of 4CMenB and 1 dose of
MenACWY-CRM in healthy at-risk adults
Germany, Italy 53 [37]
Toneatto et al. (2011) Safety, tolerability, and immunogenicity of
4CMenB in the ﬁrst human study
Switzerland 70 [38]
Santolaya et al. (2012) Immunogenicity and tolerability of 1, 2, or 3
doses of 4CMenB 1–6 months apart
Chile 1631 [39]
Read et al. (2014) Impact of Men-ACWY or 4CMenB vaccination
on  meningococcal carriage rates one month
after each vaccine course
UK 2954 [40]
Québec Ministry of
Health
Provincial vaccination campaign in
Saquenay-Lac-Saint-Jean in to all individuals
aged 2 months to 20 years
Québec, Canada 43,740 [41,42]
Perrett et al. (2014) Immunogenicity and safety equivalence of
rMenB + OMV  NZ lot 1 to rMenB + OMV  lot 2,
30  days after vaccination of 2-doses
Canada, Australia 344 [43]
Findlow et al. (2012) Safety and immunogenicity of 4CMenB and
MenACWY-CRM in UK laboratory workers
with potential occupational exposure
UK 38 [44]
CDC sponsored Safety of 4CMenB in university students
receiving vaccination during campus outbreak
US (Princeton University) 5471 [45,58]
CDC sponsored Safety of 4CMenB in university students
receiving vaccination during campus outbreak
US (University of California at
Santa Barbara)
9067 [45,58]
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 multi-component protein-based vaccine (4CMenB, Bexsero®,
ovartis Vaccines) was developed containing four major antigenic
omponents: factor H-binding protein (fHbp) fused with GNA2091,
eisseria adhesin A (NadA), Neisserial Heparin Binding Antigen
NHBA) fused with GNA1030, and OMV  from the New Zealand out-
reak strain NZ98/254 (NZ OMV) [33,34]. The OMV  component
ontains PorA serosubtype 1.4 [34]. These components are rele-
ant to the organism’s function, virulence, and/or survival and were
elected to provide broad coverage against circulating strains of
enB [35]. Interestingly, the vaccine components are also present
n meningococcal isolates of other serogroups allowing potential
se against meningococcal isolates belonging to non-B serogroups,
lthough this was not the initial intention for this vaccine [36].
linical trials have shown 4CMenB to induce bactericidal antibody
esponses against meningococcal antigens in a high proportion of
nfants, adolescents, and adults, with an acceptable tolerability pro-
le.
4CMenB is approved for use in 37 countries including EU/EEA
ountries, Australia, Canada, Chile, Colombia, and Uruguay and is
ecently approved in the US. A total of 9 studies (5 randomized con-
rolled, 3 open-label single-arm, 1 post-licensure) which enrolled
dolescents and adults to receive 4CMenB have been conducted
see Table 1) [37–45]. A total of 63,368 adolescents and young
dults received 4CMenB vaccination in studies conducted in the
S, Canada, Chile, UK, Germany, Switzerland, Italy and Australia.
. Immunogenicity
The 4CMenB vaccine has been shown to induce robust bacteri-
idal antibodies against strains expressing the vaccine antigens in
tudies in infants, adolescents and young adults. In total, six stud-
es included immunogenicity objectives of which the results of four
ave been published (Table 1) [37–40,43,44]. The four published
tudies supported a two-dose vaccine schedule in adolescents and
dults [37–40]. In each study, the immunogenicity objective was
o determine the proportion of subjects with human complement
erum bactericidal antibody (hSBA) titers ≥1:4, which is consid-
red to be the surrogate marker of protection. Titers ≥1:5 were
lso assessed as a more conservative threshold to ensure, with 95%
onﬁdence, that subjects with a titer ≥1:5 will have achieved a titer63,368
of at least 1:4. Reference strains (44/76-SL, 5/99, NZ98/254, and
M10713) were selected to match each one of the vaccine compo-
nents, and hSBA assay helped demonstrate responses against the
strains to determine immunogenicity of the key vaccine compo-
nents [46].
4.1. Responses to various vaccination schedules
In adolescents, different two-dose vaccine schedules were
assessed with doses administered up to 6 months apart. A phase
2b/3 trial conducted in 1631 Chilean adolescents aged 11–17 years
looked at the immunogenicity of 4CMenB after administration of
1, 2, or 3 doses [39]. The results showed that 1 month after the
ﬁrst dose, 92–96% and 99–100% of adolescents had protective titers
(hSBA titers ≥1:4) against the 3 indicator strains tested at 1 month
after the ﬁrst dose and 1 month after the second dose, respec-
tively (Fig. 1). Note that the indicator strain for NHBA had not
been identiﬁed at the time this study was conducted and there-
fore, NHBA analyses were conducted post hoc at limited time points
(Fig. 1). No further beneﬁt was  observed after a third dose, as
assessed by the percentage of subjects achieving putatively protec-
tive titers of hSBA ≥1:4 (hereafter referred to as protective titers).
Although higher GMTs were observed in response to a third dose
in comparison to a second dose, 99–100% of subjects had already
achieved protective titers against the four vaccine components at
1 month after the second dose. Higher GMTs in response to a third
dose did not increase the percentage of subjects with hSBA titers
≥1:4 against NadA or fHbp, and it is unclear whether there is any
clinical beneﬁt of higher titers in response to the OMV  compo-
nent. Similar results were observed at 1 month after the 2-dose
schedule both in the UK among 18–24 year old university stu-
dents (99–100% achieved hSBA titers ≥1:4 against fHbp, NadA and
PorA1.4) [47] and among 11–17 year old adolescents in Canada
and Australia (99–100% achieved hSBA titers ≥1:5 against fHbp and
NadA; 75% achieved hSBA titers ≥1:5 against PorA1.4) [43]. At two
weeks after the second vaccination, 100% of subjects in the Canada
and Australia study had hSBA titers ≥1:5 against strains fHbp and
NadA; the percentage of subjects with hSBA ≥1:5 against strain NZ
OMV  at two  weeks was higher compared to 1 month after vacci-
nation (84–96%, 64–80%, respectively) [43]. These results support
4440 T. Nolan et al. / Vaccine 33 (2015) 4437–4445
Fig. 1. Percentages of adolescents aged 11–17 years with hSBA titers ≥1:4 and GMTs at one month post vaccination with 4CMenB. Factor H-binding protein (fHbp); Neisseria
adhesion A (NadA); Neisserial heparin binding antigen (NHBA); Outer membrane vesicle (OMV). Note: Numbers above bars show geometric mean titers (GMT) of hSBA
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ource: fHbp, NadA, and PorA-OMV adapted from Ref. [39]. Supplementary web app
haracteristics: Annex 1. http://ec.europa.eu/health/documents/community-regist
he use of a 2-dose 4CMenB schedule in adolescents and young
dults.
.2. Antibody persistence 1–2 years post-vaccination
Antibody persistence after 4CMenB vaccination was evaluated
n two clinical studies up to two years after the second vaccina-
ion in subjects aged 11–25 years at the time of enrollment [47,48].
ersistence of bactericidal antibodies was measured by assessing
oth the percentage of subjects with hSBA titers ≥1:4 over time, as
ell as geometric mean titers (GMTs) against the components in
he vaccine.
In a study conducted in the UK, university students were admin-
stered a two-dose series of 4CMenB and 85–97% of students aged
9–25 years maintained hSBA titers ≥1:4 against each of the four
accine components for at least 11 months after the second dose
47]. In another study, a subset of adolescents from a phase 2b/3
tudy in Chile was enrolled in an extension study, along with an
dditional cohort of 4CMenB-naïve subjects, aged 13–19 years [48].
f 1625 eligible participants from the original Chilean study, 666
41%) were followed for antibody persistence along with 151 newly
ecruited 4CMenB-naïve control subjects. Persistence was mea-
ured 18–24 months after the primary 2-dose series, which showed
7–94% of adolescents with putatively protective hSBA titers ≥1:4
77% PorA1.4; 82% fHbp; 94% NadA). These results conﬁrm that two
oses of 4CMenB, administered 1–6 months apart, provide levels
f antibodies considered protective against MenB for at least two
ears.
. Safety
The safety of 4CMenB has been evaluated in 4697 adolescents
nd young adults across four pre-licensure Novartis-sponsored
tudies (Table 2) [37–40]. In addition, safety data on serious
dverse events (SAEs) among 14,538 university students and staff
ere collected under an expanded-use Investigational New Drug
IND) recommendation by the US Centers for Disease Control and: Web  Tables 1a–1c. *NHBA adapted from the European Union, Summary of Product
3/20130114125155/anx 125155 en.pdf.
Prevention (CDC) to address two  MenB outbreaks at university
campuses during 2013 [45–58].
In the four Novartis-sponsored randomized clinical studies,
solicited adverse events (AEs) were collected from a majority of
subjects and unsolicited medically attended and SAEs were col-
lected from all subjects [37–40]. Overall, these studies showed that
4CMenB was  generally well-tolerated with no signals of safety con-
cerns. Fig. 2 compares rates of solicited local and systemic reactions
in adolescents aged 11–18 years among vaccine and placebo recip-
ients in the Chilean adolescent study [39]. The most commonly
reported local reaction was pain at the injection site, experienced
by 86% of 4CMenB subjects versus 60% in the placebo group. The
most common systemic reaction was malaise with 51% reported in
4CMenB subjects compared to 30% for placebo. Fever was reported
in a low percentage of subjects after ﬁrst and second vaccinations
(0–2% across vaccine groups). None of the subjects reported fever
after the third dose and booster vaccinations. Similar results were
found in the other three studies (Table 2).
6. Strain coverage of 4CMenB vaccination
The diversity of relevant surface antigens targeted by vaccine-
induced antibodies has been a barrier to develop a serogroup B
meningococcal vaccine with a meaningful breadth of potential cov-
erage. The aim in utilizing various antigenic components, each
targeting antigens which are relatively conserved, is to increase
the coverage of a vaccine. Thus, while an OMV  vaccine has its lim-
itations in that it is strain-speciﬁc, the multi-component vaccine
4CMenB has demonstrated the potential for a wide breadth of cov-
erage [49].
Reverse vaccinology was  used to assess the genome of a MenB
strain in order to identify genes associated with expression of
surface proteins that displayed the ability to induce bactericidal
activity against MenB in animal models [50]. The meningococcal
antigen typing system (MATS) was  developed to predict 4CMenB
coverage in a given region by estimating coverage against a panel
of strain isolates from that region. MATS combines conventional
T. Nolan et al. / Vaccine 33 (2015) 4437–4445 4441
Table  2
Summary of key safety ﬁndings for 4CMenB studies in adolescents.
Study [Ref] Age at enrollment Participants evaluated
(countries)
Study design General safety ﬁndings
Kimura et al.
Clin Vac Immunol, 2011
[37]
18–50 years 53 adults (Italy, Germany) Open-label, multi-center,
safety, and immunogenicity
study in healthy (at-risk) adults
Most common systemic reactions:
malaise (4CMenB, ∼53%, after three
doses)
Most common local reaction: injection
site pain (4CMenB, 100%, after three
doses)
Events judged as possibly and probably
related to 4CMenB: 7 subjects who
experiences at least one adverse event
were possibly related to either 4CMenB
or MenACWY vaccination
Toneatto et al. Hum Vac, 2011
[38]
18–40 years 70 adults (Switzerland) Observer blind, single-center,
randomized, safety, and
immunogenicity study in
healthy adults
Most common systemic reactions:
myalgia (4CMenB, ∼83%; rMenB, ∼85%;
rMenB + OMVNWa, ∼71%, after two
doses)
Most common local reaction: injection
site pain (4CMenB, ∼100%; rMenB,
∼100%; rMenB + OMVNW, ∼86%, after
two  doses)
Events judged as possibly and probably
related to 4CMenB: 1 case of pruritus
Santolaya et al. Lancet, 2012
[39]
11–17 years 1631 adolescents (Chile) Observer-blind, multi-center,
randomized, controlled, safety,
and immunogenicity study in
healthy adolescents with
various schedules
Most common systemic reactions:
malaise (4CMenB, 51%; placebo, 30%) and
headache (4CMenB, 42%; placebo, 27%).
Most common local reaction: pain
(4CMenB, 86%; placebo, 60%).
Events judged as possibly and probably
related to 4CMenB: 2 cases of juvenile
arthritis, assessed as possibly and
probably related to 4CMenB reported
170 days and 198 days after the third
dose of 4CMenB.
Read  et al.
Lancet, 2014
[40]
18–24 years 2943 adults (UK) Observer-blind, multi-center,
randomized, controlled,
pharyngeal carriage study in
young adults
Most common systemic reactions:
myalgia (4CMenB, 75%; placebo, 50%)
Most common local reaction: injection
site pain (4CMenB, 93%; placebo, 48%)
Events judged as possibly and probably
related to 4CMenB: a case of dyspnea,
hand tremors, and acute thyroiditis
occurring 2, 18, and 18 days
post-vaccination.
a Recombinant meningococcal serogroup B vaccine (rMenB); outer membrane vesicle (OMV) from the Norwegian (NW) outbreak strain.
Note:  Table 2 has fewer studies listed than in Table 1. This is due to safety data not yet published or available for some studies at the time this paper was  written.
Fig. 2. Reactogenicity to doses of 4CMenB and placebo in adolescents in Chile. Note: 330 doses of 4CMenB, 2739 doses of Placebo.
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enotyping for PorA with a specialized sandwich enzyme-linked
mmunosorbent assay (ELISA) to assess the phenotypic expression
nd cross-reactivity of the remaining vaccine antigens (fHbp, NadA,
nd NHBA) on the MenB surface [50]. The 4CMenB coverage esti-
ate is determined by computing the percentage of regional strains
hat meet a minimum threshold of reactivity in the MATS-ELISA
nd/or contain the PorA 1.4 antigen. The minimum threshold is an
ntigen-speciﬁc minimum that is predictive of killing in the hSBA.
sing this method, it has been estimated that 78% of MenB strains
ould be covered by vaccination with 4CMenB across Europe [49].
mportantly, a study performed on strains collected from England
nd Wales from 2007 to 2008 to compare with bactericidal anti-
ody response in infants and adolescents, MATS was  shown to
roduce a conservative estimate of 4CMenB coverage [51]. Globally,
CMenB coverage has been evaluated in 13 countries on more than
700 strains with individual country coverage estimates ranging
rom 66% in Canada to 91% in the US [49,51–57].
. 4CMenB vaccination effect on nasopharyngeal carriage
4CMenB can be considered not only for its potential for direct
rotection in adolescents and young adults but also to induce herd
rotection by limiting acquisition in unvaccinated populations.
hristensen et al. carried out a systematic and meta-analysis review
f previous observational studies that reported pharyngeal carriage
f all meningococcal serogroups [10]. They evaluated studies con-
ucted in 28 countries in Europe, the Americas, and the Caribbean in
rder to identify age speciﬁc patterns in overall carriage; the anal-
ses were not stratiﬁed by serogroup or strain. This study showed
stimated carriage prevalence of 4.5% in infants to 7.7% in 10-year
lds, peaking at 23.7% in 19-year olds, and 7.8% in 50-year olds. This
tudy underscores the potential relevance of a vaccine reducing
arriage in adolescent populations.
To better understand whether such a protein-based meningo-
occal vaccine might impact carriage, a clinical study was
erformed in 2954 UK university students, randomized to
eceive 4CMenB, a quadrivalent meningococcal conjugate vaccine
MenACWY-CRM) or a control vaccine [40]. Students were enrolled
n the ﬁrst three months of the academic year. One month after
he second dose, there were no signiﬁcant differences in carriage
etween those in the 4CMenB and the control group (OR = 1.2, 95%
I: 0.8–1.7). However, three to twelve months after the second
ose, the 4CMenB group had signiﬁcantly lower carriage of capsu-
ar groups BCWY, with 26.6% (95% CI: 10.5–39.9) carriage reduction
ompared to the control group. It is worth noting that 4CMenB was
dministered in a 2-dose series, but because the highest acquisi-
ion was observed between the ﬁrst two study visits, the study
accines may  have been administered too late to observe a maxi-
al  impact. However, over the course of the study, a reduction in
eningococcal carriage rates was observed in both the 4CMenB
roup (1–10 months post vaccination) and the MenACWY-CRM
roup (1–11 months post vaccination), showing a potential impact
n acquisition.
. Use of 4CMenB to address outbreaks in college settings
Recent outbreaks of serogroup B meningococcal disease origi-
ated at Princeton University in March 2013 and at the University
f California at Santa Barbara (UCSB) in November 2013, result-
ng in 13 cases and 1 death [45,58–61]. Since 4CMenB was not
pproved for use in the US at the time of the outbreaks, the CDC
esponded by recommending 4CMenB under an expanded-use IND
ecommendation by the US CDC for use in the student populations
t Princeton and UCSB [45,58]. Safety surveillance was  conducted
y the CDC in cooperation with the universities. The CDC had not (2015) 4437–4445
yet published their report on these outbreaks at the time of this
writing. However, some information regarding the outbreaks was
available on the CDC website. From March to November 2013, eight
cases of MenB disease were reported at Princeton University, with
an attack rate of 134/100,000 among undergraduates [45,58]. Two
of the eight cases were left with serious sequelae (neurocognitive
deﬁcit, hearing loss) and there were no fatalities among these eight
cases [45]. A total of 5772 individuals were recommended for vac-
cination and 5502 (95%) individuals at Princeton had received the
ﬁrst dose and 5139 (89%) had received the second dose of 4CMenB
as of April 2014. As of February 2014, SAEs were reported at a
rate of 2/1000 vaccinees following the ﬁrst dose and at a rate of
0.2/1000 vaccinees following the second dose; none of these SAEs
had been determined to be causally related to the vaccine [45]. A
case of MenB disease was reported at Drexel University in March
2014 that resulted in death [61]. This case was found to be caused
by the same strain identiﬁed in the Princeton outbreak and the
student in question had been in close contact with students from
Princeton University about a week before becoming ill. Antibiotic
prophylaxis was  recommended and administered to close contacts
of the Drexel University student but widespread vaccination was
not undertaken [61].
The outbreak that occurred at UCSB during the same time period
was caused by a genetically unrelated MenB strain [45,58]. There
were four cases among undergraduates at UCSB from March to
November 2013, for an attack rate of 21.1/100,000 [59]. Although
these students recovered, one was left with serious sequelae (bilat-
eral foot amputation) [45]. Approximately 17,000 students at UCSB
had been vaccinated as of February 2014 [59]. No information
regarding AEs was available at the time of this writing. These uni-
versity outbreaks of meningococcal serogroup B underscored the
need for a MenB vaccine to be approved in the US. Subsequently, the
submission for a biologics license application (BLA) for 4CMenB was
ﬁled and has now been approved in the US for use in adolescents
and young adults, 10–25 years of age.
9. Post-licensure experience with 4CMenB in
Saguenay-Lac-Saint-Jean, Québec
In Québec, Canada, following introduction of the MCCV,
although there was reduction in serogroup C disease, there was
an increase in serogroup B incidence across all age groups, par-
ticularly in young children and adolescents [18]. Therefore, shortly
after approval of 4CMenB, the Committee on Immunization Québec
(CIQ) under the Institute National Public Health (Institut National
de Santé Publique du Québec (INSPQ)) decided to implement a
vaccination campaign in Saguenay-Lac-Saint-Jean in May  2014
in all individuals aged 2 months to 20 years [41,42]. This rep-
resents the ﬁrst public program to provide 4CMenB to a broad
population. 43,740 children, adolescents, and young adults had
received at least the ﬁrst dose as of June 2014 [42]. The Ministry of
Health in Québec also undertook active safety surveillance based on
parent-completed diary cards. Of the 43,740 vaccinees, electronic
questionnaires were completed for 12,332. Fever within 48 h post-
vaccination was  reported by 9% of respondents and 1.9% reported
fever within 3–7 days. Fever incidence was higher in children <2
years (14–15%) than in children 2–4 years and 5 years and older
(12% and 6–8%, respectively). Antipyretic prophylaxis reduced the
probability of fever within 48 h post-vaccination in children <2
years by approximately 50%. The most frequently reported health
problems were malaise (56%), local reactions (49%), gastrointestinal
(34%), or respiratory problems (24%). Open-ended written com-
ments were provided by 20% of respondents, of whom 83% cited
injection site pain. One case of febrile seizure was identiﬁed and
no hospitalizations related to the vaccine were reported. This
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arge-scale safety surveillance study did not reveal any serious or
nusual health problems associated with 4CMenB.
0. Discussion
Adolescents and young adults constitute a high-risk age group
or IMD  and the majority of cases could be vaccine-preventable. The
ncidence of IMD  due to speciﬁc serogroups, including serogroup B,
aries over geographic regions and over time [1,4–9]. Despite rapid,
igh quality medical care, meningococcal disease can be fatal and is
ssociated with long-term sequelae such as loss of limbs, cognitive
mpairment, deafness, and deﬁcit in physical functions. Further-
ore, adolescents typically have higher rates of carriage than other
ge groups and thus could serve as a source of transmission to other
t-risk groups [40].
Two recent outbreaks at Princeton University and UCSB high-
ighted the need for a meningococcal B vaccine in US adolescents
nd young adults. Although two vaccines against MenB disease
ave recently been licensed for use in the US [Trumenba® (rLP2086,
ﬁzer), Bexsero® (4CMenB, Novartis)], neither had been approved
t the time of these outbreaks. The occurrences at both Prince-
on University and UCSB resulted in 13 cases, 1 death, and serious
equelae. The emergency vaccination against MenB disease at both
niversities with 4CMenB appeared to have been successful in con-
rolling the outbreaks [45,58]. The economic and social costs of the
esponse to the outbreaks have not been quantiﬁed for MenB, but
revious analyses on the burden of MenC outbreaks have been esti-
ated on a range of $13–28 million in health care costs [62]. While
accine use in outbreak situations is promising, due to the sporadic
nd rapid nature of outbreaks, intervention is oftentimes unable to
revent secondary cases. Thus, implementation of a national immu-
ization program for vaccinating adolescents and young adults
gainst MenB is currently a strategy to consider in the US to address
his unmet medical need [63].
The adolescent population is known for non-optimal compli-
nce when it comes to completing scheduled vaccinations [64]. In
esponse, some countries have successfully implemented school-
ased vaccination programs or mandatory school and/or college
ntry requirements. Particularly in countries that do not (uni-
ersally) have such programs, a shorter dose schedule, with as
ew doses as possible, typically helps to improve schedule com-
liance. Two and 3-dose vaccination schedules were investigated
n the 4CMenB development program. The two-dose schedule
esulted in nearly all (99–100%) participants with protective titers
t one month post-second-dose, indeed even after only one dose
2–96% of adolescents had protective hSBA titers. Furthermore,
5% of participants maintained protective antibodies against MenB
or at least two years. These results support the administra-
ion of a 2- rather than 3-dose series. In addition, post-licensure
tudies are required to determine vaccine effectiveness as well
s persistence in adolescents and young adults. As more data
s gathered from post-licensure studies, the suitability of a 2-
ose schedule could be made clearer. Fewer doses may  help to
mprove compliance in this population known for poor compli-
nce and partial protection could be expected even after the ﬁrst
ose.
4CMenB has been designed to provide broad coverage against
he diverse strains of meningococcal B. As a result of the demon-
trated effectiveness of OMV-based vaccines to control regional
utbreaks of speciﬁc MenB strains, the OMV  component PorA
.4 was selected for inclusion in 4CMenB. However, the effec-
iveness of an OMV-based vaccine is limited to strains that
ontain the same PorA protein (particularly in young children).
herefore, reverse vaccinology was used to perform a complete
nalysis of the genetic sequence of a MenB strain in order to (2015) 4437–4445 4443
systematically identify surface-exposed proteins [50]. These were
then screened for their ability to induce bactericidal activity
against MenB, and the most promising of these, fHbp, NadA, and
NHBA, were included in the formulation of 4CMenB. Based on
an assessment performed on a large panel of 442 representa-
tive meningococcal B strains from the US, MATS showed that 91%
of these strains are predicted to be covered by 4CMenB-elicited
immune sera.
4CMenB elicits robust immune responses in adolescents and
adults, as well as in infants and older children [37,39,65–68]. Clin-
ical studies have shown that the vaccine has an acceptable safety
proﬁle. In adolescents and adults, rates of solicited AEs, especially
injection site pain, occurred more frequently in 4CMenB recipients
than in the control/placebo groups. However, most reactions were
mild or moderate in severity and of limited duration. Finally, while
preliminary safety data looks promising, post-licensure safety data
is expected shortly from studies conducted in large populations
during the vaccination campaigns at Princeton University, UCSB,
and Québec. As for all new vaccines, larger phase IV studies after
more widespread use will be required to evaluate possible rarer
AEs.
Unexpected outbreaks of MenB disease at various institutions in
the US, provinces in Canada, and other world regions highlight the
need for an effective and preventative intervention on a national
level. The vast majority of IMD  is caused by serogroups A, B, C,
W, and Y. In addition to currently available MenACWY vaccines,
the utilization of a well-tolerated and highly immunogenic vaccine
against MenB offers the possibility to help prevent most IMD.
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